Literature DB >> 23962442

Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline.

Chiara Bianca Maria Platania1, Gian Marco Leggio, Filippo Drago, Salvatore Salomone, Claudio Bucolo.   

Abstract

Elevated intraocular pressure (IOP) is the main recognized risk factor of glaucoma. To investigate the contribution of dopaminergic and serotonergic systems in IOP regulation, we used cabergoline, a mixed dopamine and serotonin agonist, in C57BL/6J WT and dopamine D₃ receptor knock-out (D₃R⁻/⁻) mice with normal eye pressure or steroid-induced ocular hypertension. Furthermore, we studied the structural basis of the cabergoline-mediated activation of the dopaminergic and serotonergic systems by molecular modeling. Topical application of cabergoline, significantly decreased, in a dose-dependent manner, the intraocular pressure in WT mice, both in an ocular normotensive group (-9, -5 and -2 mmHg with 5%, 1%, and 0.1%, respectively) and an ocular hypertensive group, with a prolonged effect in this latter group. No change of intraocular pressure was observed after topical application of cabergoline in D₃R⁻/⁻ mice. We modeled and optimized, with molecular dynamics, structures of hD₃, h5HT(1A) and h5HT(2A-C) receptors; thereafter we carried out molecular docking of cabergoline. Docking revealed that binding of cabergoline into D₃ and 5HT(1A) receptors is associated with a better desolvation energy in comparison to 5HT(2A-C) binding. In conclusion, the present study support the hypothesis that dopaminergic system is pivotal to regulate IOP and that D₃R represents an intriguing target in the treatment of glaucoma. Furthermore, the structure-based computational approach adopted in this study is able to build and refine structure models of homologous dopaminergic and serotonergic receptors that may be of interest for structure-based drug discovery of ligands, with dopaminergic selectivity or with multi-pharmacological profile, potentially useful to treat optic neuropathies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopaminergic system; GPCR; Intraocular pressure; Molecular modeling; Optic neuropathy; Serotonergic system

Mesh:

Substances:

Year:  2013        PMID: 23962442     DOI: 10.1016/j.bcp.2013.08.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Functional roles of T3.37 and S5.46 in the activation mechanism of the dopamine D1 receptor.

Authors:  Estefanía A Hugo; Bruce K Cassels; Angélica Fierro
Journal:  J Mol Model       Date:  2017-03-31       Impact factor: 1.810

Review 2.  Animal models of glucocorticoid-induced glaucoma.

Authors:  Darryl R Overby; Abbot F Clark
Journal:  Exp Eye Res       Date:  2015-06-04       Impact factor: 3.467

3.  Homology modeling, molecular dynamic simulation, and docking based binding site analysis of human dopamine (D4) receptor.

Authors:  Minasadat Khoddami; Hamid Nadri; Alireza Moradi; Amirhossein Sakhteman
Journal:  J Mol Model       Date:  2015-02-04       Impact factor: 1.810

Review 4.  Neuroprotective strategies for retinal disease.

Authors:  Machelle T Pardue; Rachael S Allen
Journal:  Prog Retin Eye Res       Date:  2018-02-23       Impact factor: 21.198

Review 5.  Novel Therapeutics in Glaucoma Management.

Authors:  Claudio Bucolo; Chiara Bianca Maria Platania; Filippo Drago; Vincenza Bonfiglio; Michele Reibaldi; Teresio Avitabile; Maurizio Uva
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

6.  Prediction and Identification of GPCRs Targeting for Drug Repurposing in Osteosarcoma.

Authors:  Manli Tan; Shangzhi Gao; Xiao Ru; Maolin He; Jinmin Zhao; Li Zheng
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

Review 7.  Crosstalk Between Dysfunctional Mitochondria and Inflammation in Glaucomatous Neurodegeneration.

Authors:  Assraa Hassan Jassim; Denise M Inman; Claire H Mitchell
Journal:  Front Pharmacol       Date:  2021-07-21       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.